FI880017A - Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu - Google Patents
Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu Download PDFInfo
- Publication number
- FI880017A FI880017A FI880017A FI880017A FI880017A FI 880017 A FI880017 A FI 880017A FI 880017 A FI880017 A FI 880017A FI 880017 A FI880017 A FI 880017A FI 880017 A FI880017 A FI 880017A
- Authority
- FI
- Finland
- Prior art keywords
- variants
- preparation
- trypsin inhibitor
- pancreatic secretory
- secretory trypsin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/27—Cyclic peptide or cyclic protein
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8700204 | 1987-01-07 | ||
GB08700204A GB2199582A (en) | 1987-01-07 | 1987-01-07 | Analogues of pancreatic secretory trypsin inhibitor |
Publications (4)
Publication Number | Publication Date |
---|---|
FI880017A0 FI880017A0 (fi) | 1988-01-05 |
FI880017A true FI880017A (fi) | 1988-07-08 |
FI97139B FI97139B (fi) | 1996-07-15 |
FI97139C FI97139C (fi) | 1996-10-25 |
Family
ID=10610323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI880017A FI97139C (fi) | 1987-01-07 | 1988-01-05 | Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu |
Country Status (15)
Country | Link |
---|---|
US (1) | US5126322A (fi) |
EP (1) | EP0278112B1 (fi) |
JP (2) | JPS63169994A (fi) |
KR (1) | KR960010949B1 (fi) |
CN (1) | CN1030999C (fi) |
AT (1) | ATE97421T1 (fi) |
AU (1) | AU592486B2 (fi) |
DE (1) | DE3788216D1 (fi) |
DK (1) | DK3688A (fi) |
ES (1) | ES2059356T3 (fi) |
FI (1) | FI97139C (fi) |
GB (1) | GB2199582A (fi) |
HU (1) | HUT46068A (fi) |
IL (1) | IL85020A (fi) |
ZA (1) | ZA8860B (fi) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8894994B2 (en) | 2010-05-24 | 2014-11-25 | Synthetic Biologics, Inc. | Modified beta-lactamases and methods and uses related thereto |
US9290754B2 (en) | 2014-04-17 | 2016-03-22 | Synthetic Biologics Inc. | Beta-lactamases with improved properties for therapy |
US9744221B2 (en) | 2014-12-23 | 2017-08-29 | Synthetic Biologics, Inc. | Method and compositions for inhibiting or preventing adverse effects of oral antibiotics |
US10105322B2 (en) | 2014-10-08 | 2018-10-23 | Synthetic Biologics, Inc. | Beta-lactamase formulations and uses thereof |
US10548955B2 (en) | 2015-02-23 | 2020-02-04 | Synthetic Biologics, Inc. | Carbapenemases for use with antibiotics for the protection of the intestinal microbiome |
US10709773B2 (en) | 2015-03-06 | 2020-07-14 | Synthetic Biologics, Inc. | Safe and effective beta-lactamase dosing for microbiome protection |
US11034966B2 (en) | 2014-08-28 | 2021-06-15 | Synthetic Biologics, Inc. | E. coli-based production of beta-lactamase |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8172787A (en) * | 1986-10-30 | 1988-05-25 | Synergen Biologicals, Inc. | Human pancreatic secretory trypsin inhibitors produced by recombinant dna methods and processes for the production of same |
JPS6427473A (en) * | 1987-07-23 | 1989-01-30 | Mochida Pharm Co Ltd | Human pancreas-secreting trypsin inhibitor and production thereof |
GB2208511A (en) * | 1987-08-07 | 1989-04-05 | Bayer Ag | Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology |
US5591603A (en) * | 1987-08-28 | 1997-01-07 | Novo Nordisk A/S | Process for preparing aprotinin and aprotinin analogs in yeast cells |
ES2063161T3 (es) * | 1988-03-07 | 1995-01-01 | Ciba Geigy Ag | Proteinas modificadas. |
US5180667A (en) * | 1988-03-07 | 1993-01-19 | Ciba-Geigy Corporation | Genes encoding eglin C mutants |
JPH07102137B2 (ja) * | 1988-07-19 | 1995-11-08 | 塩野義製薬株式会社 | 修飾ヒトpsti |
DE3907492A1 (de) * | 1989-03-08 | 1990-09-13 | Biotechnolog Forschung Gmbh | Verfahren zur isolierung und reinigung von hpsti und hpsti-varianten |
US5231010A (en) * | 1989-09-13 | 1993-07-27 | Bayer Aktiengesellschaft | Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof |
IL104314A0 (en) * | 1992-01-07 | 1993-05-13 | Novo Nordisk As | Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them |
EP0699750A1 (en) * | 1994-06-07 | 1996-03-06 | Gesellschaft für biotechnologische Forschung mbH (GBF) | A collection of phagemids, a collection of Escherichia coli cells carrying the phagemids, a collection of phagemid particles produced from said collection and phagemid particles obtained according to the process |
JPH09124698A (ja) | 1995-10-27 | 1997-05-13 | Sagami Chem Res Center | ヒトpec−60様蛋白質およびそれをコードするdna |
US6703201B1 (en) | 1995-10-27 | 2004-03-09 | Sagami Chemical Research Center | Human PEC-60-like protein and DNA encoding this protein |
US5851987A (en) * | 1997-04-14 | 1998-12-22 | Incyte Pharmaceuticals, Inc. | Human tumor-associated Kazal inhibitor-like polypeptides and encoding polynucleotides |
WO2008052238A1 (en) * | 2006-11-01 | 2008-05-08 | The University Of Sydney | Treatment of urological cancer |
ES2753183T3 (es) | 2007-02-12 | 2020-04-07 | Csl Behring Gmbh | Aplicación terapéutica de inhibidores de la proteasa de serina de tipo Kazal |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2701890C2 (de) * | 1977-01-19 | 1983-08-04 | Hoechst Ag, 6230 Frankfurt | Peptielischer Glycosidhydrolase-Inhibitor aus einem Streptomyceten und seine Verwendung |
AU560584B2 (en) * | 1983-07-28 | 1987-04-09 | Bayer Aktiengesellschaft | Homologues of aprotinin |
DE3429430A1 (de) * | 1984-08-10 | 1986-02-20 | Hoechst Ag, 6230 Frankfurt | Gentechnologisches verfahren zur herstellung von hirudin und mittel zur durchfuehrung dieses verfahrens |
IL77227A (en) * | 1984-12-06 | 1992-08-18 | Synergen Biolog Inc | Recombinant methods for production of serine protease inhibitors and methods for isolation of same |
US4760130A (en) * | 1984-12-06 | 1988-07-26 | Synergen Biologicals, Inc. | Serine protease inhibitors and methods for isolation of same |
JPH0616716B2 (ja) * | 1986-10-14 | 1994-03-09 | 塩野義製薬株式会社 | 酵母におけるヒトpstiの製造法 |
KR960013466B1 (ko) * | 1986-10-14 | 1996-10-05 | 시오노기 세이야꾸 가부시끼가이샤 | 단백질의 신규제법 |
AU8172787A (en) * | 1986-10-30 | 1988-05-25 | Synergen Biologicals, Inc. | Human pancreatic secretory trypsin inhibitors produced by recombinant dna methods and processes for the production of same |
-
1987
- 1987-01-07 GB GB08700204A patent/GB2199582A/en active Pending
- 1987-12-24 DE DE87119221T patent/DE3788216D1/de not_active Expired - Lifetime
- 1987-12-24 ES ES87119221T patent/ES2059356T3/es not_active Expired - Lifetime
- 1987-12-24 AT AT87119221T patent/ATE97421T1/de not_active IP Right Cessation
- 1987-12-24 EP EP87119221A patent/EP0278112B1/de not_active Expired - Lifetime
-
1988
- 1988-01-04 IL IL85020A patent/IL85020A/xx not_active IP Right Cessation
- 1988-01-05 FI FI880017A patent/FI97139C/fi not_active IP Right Cessation
- 1988-01-05 HU HU8817A patent/HUT46068A/hu unknown
- 1988-01-05 AU AU10038/88A patent/AU592486B2/en not_active Ceased
- 1988-01-06 DK DK003688A patent/DK3688A/da not_active Application Discontinuation
- 1988-01-06 JP JP63000445A patent/JPS63169994A/ja active Pending
- 1988-01-06 ZA ZA8860A patent/ZA8860B/xx unknown
- 1988-01-07 CN CN88100146A patent/CN1030999C/zh not_active Expired - Fee Related
- 1988-01-07 KR KR1019880000044A patent/KR960010949B1/ko not_active IP Right Cessation
-
1991
- 1991-04-16 US US07/685,798 patent/US5126322A/en not_active Expired - Fee Related
-
1997
- 1997-07-30 JP JP9218307A patent/JPH10117786A/ja active Pending
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8894994B2 (en) | 2010-05-24 | 2014-11-25 | Synthetic Biologics, Inc. | Modified beta-lactamases and methods and uses related thereto |
US9034602B2 (en) | 2010-05-24 | 2015-05-19 | Synthetic Biologics, Inc. | Modified beta-lactamases and methods and uses related thereto |
US11214787B2 (en) | 2010-05-24 | 2022-01-04 | Synthetic Biologies, Inc. | Modified beta-lactamases and methods and uses related thereto |
US9301995B2 (en) | 2010-05-24 | 2016-04-05 | Synthetic Biologics, Inc. | Modified beta-lactamases and methods and uses related thereto |
US9301996B2 (en) | 2010-05-24 | 2016-04-05 | Synthetic Biologics, Inc. | Modified beta-lactamases and methods and uses related thereto |
US10253306B2 (en) | 2010-05-24 | 2019-04-09 | Synthetic Biologics, Inc. | Modified beta-lactamases and methods and uses related thereto |
US10041056B2 (en) | 2010-05-24 | 2018-08-07 | Synthetic Biologics, Inc. | Modified beta-lactamases and methods and uses related thereto |
US9765320B2 (en) | 2010-05-24 | 2017-09-19 | Synthetic Biologics, Inc. | Modified beta-lactamases and methods and uses related thereto |
US9587234B2 (en) | 2010-05-24 | 2017-03-07 | Synthetic Biologics, Inc. | Modified beta-lactamases and methods and uses related thereto |
US9695409B2 (en) | 2014-04-17 | 2017-07-04 | Synthetic Biologics, Inc. | Beta-lactamases with improved properties for therapy |
US9290754B2 (en) | 2014-04-17 | 2016-03-22 | Synthetic Biologics Inc. | Beta-lactamases with improved properties for therapy |
US9464280B1 (en) | 2014-04-17 | 2016-10-11 | Synthetic Biologics, Inc. | Beta-lactamases with improved properties for therapy |
US9783797B1 (en) | 2014-04-17 | 2017-10-10 | Synthetic Biologics, Inc. | Beta-lactamases with improved properties for therapy |
US10011824B2 (en) | 2014-04-17 | 2018-07-03 | Synthetic Biologics, Inc. | Beta-lactamases with improved properties for therapy |
US9404103B1 (en) | 2014-04-17 | 2016-08-02 | Synthetic Biologics, Inc. | Beta-lactamases with improved properties for therapy |
US11608494B2 (en) | 2014-04-17 | 2023-03-21 | Theriva Biologics, Inc. | Beta-lactamases with improved properties for therapy |
US10087433B1 (en) | 2014-04-17 | 2018-10-02 | Synthetic Biologics, Inc. | Beta-lactamases with improved properties for therapy |
US11236319B2 (en) | 2014-04-17 | 2022-02-01 | Synthetic Biologies, Inc. | Beta-lactamases with improved properties for therapy |
US9376673B1 (en) | 2014-04-17 | 2016-06-28 | Synthetic Biologics, Inc. | Beta-lactamases with improved properties for therapy |
US10336995B2 (en) | 2014-04-17 | 2019-07-02 | Synthetic Biologics, Inc. | Beta-lactamases with improved properties for therapy |
US10767171B2 (en) | 2014-04-17 | 2020-09-08 | Synthetic Biologics, Inc. | Beta-lactamases with improved properties for therapy |
US10584326B2 (en) | 2014-04-17 | 2020-03-10 | Synthetic Biologics, Inc. | Beta-lactamases with improved properties for therapy |
US11034966B2 (en) | 2014-08-28 | 2021-06-15 | Synthetic Biologics, Inc. | E. coli-based production of beta-lactamase |
US11542510B2 (en) | 2014-08-28 | 2023-01-03 | Synthetic Biologics, Inc. | E. coli-based production of beta-lactamase |
US10828260B2 (en) | 2014-10-08 | 2020-11-10 | Synthetic Biologics, Inc. | Beta-lactamase formulations and uses thereof |
US10105322B2 (en) | 2014-10-08 | 2018-10-23 | Synthetic Biologics, Inc. | Beta-lactamase formulations and uses thereof |
US10792346B2 (en) | 2014-12-23 | 2020-10-06 | Synthetic Biologics, Inc. | Method and compositions for inhibiting or preventing adverse effects of oral antibiotics |
US9744221B2 (en) | 2014-12-23 | 2017-08-29 | Synthetic Biologics, Inc. | Method and compositions for inhibiting or preventing adverse effects of oral antibiotics |
US11596674B2 (en) | 2014-12-23 | 2023-03-07 | Synthetic Biologies, Inc. | Method and compositions for inhibiting or preventing adverse effects of oral antibiotics |
US10046035B2 (en) | 2014-12-23 | 2018-08-14 | Synthetic Biologics, Inc. | Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics |
US11944669B2 (en) | 2014-12-23 | 2024-04-02 | Theriva Biologics, Inc. | Method and compositions for inhibiting or preventing adverse effects of oral antibiotics |
US11123413B2 (en) | 2015-02-23 | 2021-09-21 | Synthetic Biologies, Inc. | Carbapenemases for use with antibiotics for the protection of the intestinal microbiome |
US10548955B2 (en) | 2015-02-23 | 2020-02-04 | Synthetic Biologics, Inc. | Carbapenemases for use with antibiotics for the protection of the intestinal microbiome |
US10709773B2 (en) | 2015-03-06 | 2020-07-14 | Synthetic Biologics, Inc. | Safe and effective beta-lactamase dosing for microbiome protection |
US11253577B2 (en) | 2015-03-06 | 2022-02-22 | Synthetic Biologics, Inc. | Safe and effective beta-lactamase dosing for microbiome protection |
US11872268B2 (en) | 2015-03-06 | 2024-01-16 | Theriva Biologics, Inc. | Safe and effective beta-lactamase dosing for microbiome protection |
Also Published As
Publication number | Publication date |
---|---|
DE3788216D1 (de) | 1993-12-23 |
KR880009125A (ko) | 1988-09-14 |
EP0278112A3 (en) | 1990-01-10 |
FI97139B (fi) | 1996-07-15 |
GB8700204D0 (en) | 1987-02-11 |
AU592486B2 (en) | 1990-01-11 |
KR960010949B1 (ko) | 1996-08-14 |
US5126322A (en) | 1992-06-30 |
GB2199582A (en) | 1988-07-13 |
EP0278112A2 (de) | 1988-08-17 |
ATE97421T1 (de) | 1993-12-15 |
ZA8860B (en) | 1988-10-26 |
JPH10117786A (ja) | 1998-05-12 |
FI97139C (fi) | 1996-10-25 |
CN1030999C (zh) | 1996-02-14 |
ES2059356T3 (es) | 1994-11-16 |
DK3688D0 (da) | 1988-01-06 |
JPS63169994A (ja) | 1988-07-13 |
FI880017A0 (fi) | 1988-01-05 |
AU1003888A (en) | 1988-09-01 |
HUT46068A (en) | 1988-09-28 |
CN88100146A (zh) | 1988-08-31 |
DK3688A (da) | 1988-07-08 |
IL85020A (en) | 1993-02-21 |
IL85020A0 (en) | 1988-06-30 |
EP0278112B1 (de) | 1993-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI880017A (fi) | Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu | |
DE3856265D1 (de) | Varianten des pankreatischen Rinder-Trypsininhibitors, deren Herstellung und Verwendung | |
ATE81673T1 (de) | Verfahren zur beseitigung von nendaminos|ureresten aus eukaryotpolypeptidanlagen und so erzeugte polypeptide. | |
ATE90944T1 (de) | Fuer ein hirudinaehnliches protein kodierende dns- sequenz und verfahren zur herstellung eines solchen proteins. | |
DE68919246T2 (de) | Verfahren zur Herstellung von Aminosäuren. | |
HUT68021A (en) | Improved activating process of recombinant proteins | |
SE8801701D0 (sv) | Production technology based on enzymic method | |
ATE264913T1 (de) | Protease-resistente analoge des thrombomodulin | |
DE3688324D1 (de) | Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel. | |
AU5232886A (en) | Serine protease inhibitors and methods for isolation of same | |
HU9201723D0 (en) | Process for the production of herpes protheae, of preparations containing them and the use of the enzym | |
NO930428D0 (no) | Proteinstrukturen til plantetoksingelonin | |
DE59108128D1 (de) | Verfahren zur Herstellung von Fremdproteinen in Streptomyceten | |
FI830813L (fi) | Foerfarande foer omvandling av pre-proinsulinanaloger till insulin | |
DK0467839T3 (da) | In-vitro-behandling af fusionsproteiner | |
DK27097A (da) | Minactivin og fremgangsmåde til fremstilling deraf | |
ATE103341T1 (de) | Antikoerper gegen hochkonservierte aminosaeuresequenzen von immunogenen substanzen, verfahren zur herstellung dieser antikoerper, sowie deren verwendung in immunoassays. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
BB | Publication of examined application | ||
PC | Transfer of assignment of patent |
Owner name: GESELLSCHAFT FUER BIOTECHNOLOGISCHE |
|
MM | Patent lapsed |
Owner name: GESELLSCHAFT FUER BIOTECHNOLOGISCHE FORSCHUNG MBH |